Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Jul
05
Today In Oncology
Addition of Glofitamab to R-CHOP or Pola-R-CHP  in Younger Patients With High-Risk LBCL
FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma
Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo